WHO ICTRP trial
Assessment of Neublastin-Induced Skin and Sensory Alterations and Headache in…
NL-OMON49543 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON49543 |
|---|---|
| Public title | Assessment of Neublastin-Induced Skin and Sensory Alterations and Headache in Healthy Subjects and Migraine Patients |
| Scientific title | Assessment of Neublastin-Induced Skin and Sensory Alterations and Headache in Healthy Subjects and Migraine Patients - Neublastin Challenge in Healthy Subjects and Migraine Patients |
| Primary sponsor | Centre for Human Drug Research |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | Migraine;10019231;Migraine |
| Interventions | Investigational drug Neublastin (also known as BG00010) acts as a selective ligand for the GFRa3 receptor. Neublastin is supplied as a liquid drug product in vials containing 5.0 mL of 1.6 mg/mL Neublastin. The formulation is as follows… |
| Registration date | Jun 30, 2020 |
| Target size | 48 |
| Secondary IDs | 2019-001771-36;NL69885.056.19 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: